HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schinkel, A. F. L. Articles by Bax, J. J. Search for Related Content PubMed PubMed Citation Articles by Schinkel, A. F. L. Articles by Bax, J. J. Related Collections Myocardial infarction

J Thorac Cardiovasc Surg 2004;127:385-390
© 2004 The American Association for Thoracic Surgery

Surgery for acquired cardiovascular disease

Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?

^a Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
^b Department of Cardiology, University Hospital Brussels, Brussels, Belgium
^c Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Received for publication February 28, 2003; revisions received August 7, 2003; accepted for publication August 11, 2003.

^* Address for reprints: Don Poldermans, MD, PhD, Thoraxcenter Room Ba 300, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
poldermans{at}hlkd.azr.nl

OBJECTIVE: In patients with ischemic cardiomyopathy and a substantial amount of dysfunctional but viable myocardium, myocardial revascularization may improve left ventricular ejection fraction. The aim of this study was to evaluate why not all patients with a substantial amount of viable tissue recover in function after revascularization.

METHODS: A total of 118 consecutive patients with a depressed left ventricular ejection fraction (on average 29% ± 6%) due to chronic coronary artery disease underwent myocardial revascularization. Before revascularization all patients underwent dobutamine stress echocardiography to assess regional dysfunction, left ventricular volumes, and myocardial viability as well as radionuclide ventriculography to determine the left ventricular ejection fraction. Next, 3 to 6 months after revascularization, the left ventricular ejection fraction and regional contractile function were reassessed. Improvement of left ventricular ejection fraction 5% following revascularization was considered clinically significant.

RESULTS: Dobutamine stress echocardiography revealed that 489 (37%) of the 1329 dysfunctional segments were viable. A total of 61 (52%) patients had a substantial amount of viable myocardium (4 viable segments). In these 61 patients the global function was expected to recover 5% after revascularization. However, left ventricular ejection fraction did not improve in 20 (33%) of 61 patients despite the presence of substantial viability. Clinical characteristics and echocardiographic data were comparable between patients with and without improvement. However, patients without improvement had considerably larger end systolic volumes (153 ± 41 mL vs 133 ± 46 mL, P = .007). The likelihood of recovery of global function decreased proportionally with the increase of end systolic volume (P < .001, R = 0.43, n = 61). Receiver operating characteristic curve analysis demonstrated that an end systolic volume 140 mL had the highest sensitivity/specificity to predict the absence of global recovery.

CONCLUSIONS: In patients with ischemic cardiomyopathy not only the amount of dysfunctional but viable myocardium but also the extent of left ventricular remodeling determines the improvement in function following myocardial revascularization. Patients with a high end systolic volume due to left ventricular remodeling have a decreased likelihood of improvement of global function.

This article has been cited by other articles:

				T. Bove, Y. Van Belleghem, G. Vandenplas, F. Caes, K. Francois, J. De Backer, M. De Pauw, and G. Van Nooten Short-term systolic and diastolic ventricular performance after surgical ventricular restoration for dilated ischemic cardiomyopathy Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 995 - 1003. [Abstract] [Full Text] [PDF]

				V. A. Mannacio, D. Iorio, V. De Amicis, F. Di Lello, and F. Musumeci Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1541 - 1548. [Abstract] [Full Text] [PDF]

				M. H. Mandegar, M. A. Yousefnia, F. Roshanali, H. Rayatzadeh, and F. Alaeddini Interaction between two predictors of functional outcome after revascularization in ischemic cardiomyopathy: left ventricular volume and amount of viable myocardium. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 930 - 936. [Abstract] [Full Text] [PDF]

				K. Goscinska-Bis, J. Bis, M. Krejca, R. Ulczok, P. Szmagala, A. Bochenek, and W. Kargul Totally epicardial cardiac resynchronization therapy system implantation in patients with heart failure undergoing CABG Eur J Heart Fail, May 1, 2008; 10(5): 498 - 506. [Abstract] [Full Text] [PDF]

				P. G. Camici, S. K. Prasad, and O. E. Rimoldi Stunning, Hibernation, and Assessment of Myocardial Viability Circulation, January 1, 2008; 117(1): 103 - 114. [Full Text] [PDF]

				J. Lipiecki, N. Durel, and J. Ponsonnaille Which patients with ischaemic heart disease could benefit from cell replacement therapy? Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H3 - H7. [Abstract] [Full Text] [PDF]

				U. Sartipy, A. Albage, and D. Lindblom Risk factors for mortality and hospital re-admission after surgical ventricular restoration Eur. J. Cardiothorac. Surg., November 1, 2006; 30(5): 762 - 769. [Abstract] [Full Text] [PDF]

				M. Di Mauro, G. Di Giammarco, G. Vitolla, M. Contini, A. L. Iaco, A. Bivona, L. Weltert, and A. M. Calafiore Impact of No-to-Moderate Mitral Regurgitation on Late Results After Isolated Coronary Artery Bypass Grafting in Patients With Ischemic Cardiomyopathy Ann. Thorac. Surg., June 1, 2006; 81(6): 2128 - 2134. [Abstract] [Full Text] [PDF]

				G. A. Ribeiro, C. E. da Costa, M. M. Lopes, A. N. Albuquerque, F. Antoniali, G. A. A. Reinert, and K. G. Franchini Left ventricular reconstruction benefits patients with ischemic cardiomyopathy and non-viable myocardium Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 196 - 201. [Abstract] [Full Text] [PDF]

				M. Cotrufo, G. Romano, L. S. De Santo, A. D. Corte, C. Amarelli, G. Cafarella, C. Maiello, and M. Scardone Treatment of extensive ischemic cardiomyopathy: quality of life following two different surgical strategies Eur. J. Cardiothorac. Surg., March 1, 2005; 27(3): 481 - 487. [Abstract] [Full Text] [PDF]

				V Rizzello, D Poldermans, E Biagini, A F L Schinkel, R van Domburg, A Elhendy, E C Vourvouri, M Bountioukos, A Lombardo, B Krenning, et al. Improvement of stress LVEF rather than rest LVEF after coronary revascularisation in patients with ischaemic cardiomyopathy and viable myocardium Heart, March 1, 2005; 91(3): 319 - 323. [Abstract] [Full Text] [PDF]

				A. F L Schinkel, J. J Bax, and D. Poldermans Clinical assessment of myocardial hibernation Heart, January 1, 2005; 91(1): 111 - 117. [Full Text] [PDF]

				P. Fundaro, P. Tartara, and E. Vitali Moderate mitral regurgitation repair at the time of coronary bypass: When is it required? J. Thorac. Cardiovasc. Surg., November 1, 2004; 128(5): 796 - 796. [Full Text] [PDF]